EN DE
STOCK COMPARISON

Ilsung Pharm vs Jiangsu Hengrui Medicine Co: Fair Value & Quality

Both stocks run through our valuation models. Here is how Ilsung Pharm (003120) and Jiangsu Hengrui Medicine Co (600276) compare, as of Aug 11, 2026.

As of Aug 11, 2026, Fair Value Calculator sees Jiangsu Hengrui Medicine Co as the less overvalued of the two: Ilsung Pharm trades at KRW 20,450 versus a fair value of KRW 9,564 (-53%), while Jiangsu Hengrui Medicine Co trades at ¥54.18 versus ¥25.94 (-52%).
Ilsung Pharm
003120.KO · KRW · Health Care
-53%
upside to fair value
overvalued
PriceKRW 20,450
Fair ValueKRW 9,564
Quality54/100
Jiangsu Hengrui Medicine Co
600276.SHG · CNY · Health Care
-52%
upside to fair value
overvalued
Price¥54.18
Fair Value¥25.94
Quality66/100

Head-to-head numbers

Green value = the better side for that row (for valuation multiples: lower = cheaper).

Ilsung PharmJiangsu Hengrui Medicine Co
Valuation
P/E (TTM)43.6×
P/S (TTM)10.84×
P/B5.76×
EV/EBITDA33.0×
PEG0.93×
5.9%Dividend yield0.4%
KRW 1,200Dividend per share¥0.20
Profitability
2%Net margin25%
-3%Operating margin32%
0%Return on equity15%
-1%Return on assets9%
Growth
1%Revenue growth (YoY)13%
1.6%Avg. growth/yr (3Y)13.9%
9.6%Avg. growth/yr (5Y)2.5%
Balance & size
$104MMarket cap$52B
mixedGrowth qualityhealthy

Jiangsu Hengrui Medicine Co leads: 2 to 6 metric wins.

Dash = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

Ilsung Pharmof which business quality 55 · market factors 38 Jiangsu Hengrui Medicine Coof which business quality 68 · market factors 47
ProfitabilityMargins and returns on capital today
14
63
Quality GrowthAre margins and returns improving?
51
41
CashflowEarnings quality: real cash, not paper profit
43
82
Fin. StrengthBalance sheet, leverage, solvency risk
100
100
InvestmentDisciplined investing over empire-building
97
27
Low VolatilityCalm price path (market factor)
76
78
MomentumPrice trend over the last 3–12 months (market factor)
24
37
52W MomentumDistance to the 52-week high (market factor)
18
29
Net IssuanceBuybacks instead of dilution
40
64

What the models say

The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.

Ilsung Pharm

DCF ModelsKRW 19,939
Earnings-BasedKRW 1,353
Dividend DiscountKRW 10,263
MultiplesKRW 3,174
Asset-BasedKRW 36,142
Growth DCFKRW 20,007
Economic ProfitKRW 33,651
Growth EarningsKRW 2,705

15 of 18 models see the stock below the current price.

Jiangsu Hengrui Medicine Co

DCF Models¥37.78
Earnings-Based¥21.29
Dividend Discount¥3.82
Multiples¥23.65
Asset-Based¥6.44
Growth DCF¥39.88
Economic Profit¥18.21
Growth Earnings¥30.99

26 of 26 models see the stock below the current price.

Scenario ranges

From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.

Ilsung Pharm
Bear KRW 8,738Fair Value KRW 9,564Bull KRW 10,823
KRW 20,450 = current price (white tick)
Jiangsu Hengrui Medicine Co
Bear ¥19.95Fair Value ¥25.94Bull ¥40.28
¥54.18 = current price (white tick)

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

Ilsung Pharm · Health Care

Quality score54 · above median
Fair value upside-53% · below median

Jiangsu Hengrui Medicine Co · Health Care

Quality score66 · Top 25%
Fair value upside-52% · below median

Bottom line

As of Aug 11, 2026, Fair Value Calculator sees Jiangsu Hengrui Medicine Co as the less overvalued of the two: Ilsung Pharm trades at KRW 20,450 versus a fair value of KRW 9,564 (-53%), while Jiangsu Hengrui Medicine Co trades at ¥54.18 versus ¥25.94 (-52%).

Jiangsu Hengrui Medicine Co has the higher quality score (66/100).

See the full analysis →

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.